Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

The Effect of GLM 002, an Oriental Medicine, on Blood Pressure and Plasma Lipids in Spontaneously Hypertensive Rats

  • Yu Byung Soo (Department of Chemistry, Natural Science College, Wonkwang University) ;
  • Kim Hee Seok (Department of Chemistry, Natural Science College, Wonkwang University) ;
  • Keon In Sook (Department of Herbal Resources, Professional Graduate School of Oriental Medicine, Wonkwang University) ;
  • Lee Cheol Han (Department of Herbal Resources, Professional Graduate School of Oriental Medicine, Wonkwang University) ;
  • Baek Seung Hwa (Faculty of Life Science, Hanil University & Presbyterian theological Sminary)
  • Published : 2004.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Inhibition of angiotensin converting enzyme (ACE) activity is one of the common antihypertensive methods functioned by drugs such as captopril, lisinopril and enalapril to serve as inhibitors of ACE. This study was designed to compare the effects of enalapril, an angiotensin-converting enzyme inhibitor and GLM002, an oriental medicine, on tail systolic pressure, aorta and plasma properties in spontaneously hypertensive rats (SHR) after 4 weeks of treatment. During the treatment, blood pressure was depressed to normal in GLM002 and enalapril groups. The treatments of enalapril and GLM002 were discontinued in 4 weeks. One week after the treatment stop, systolic blood pressure was smoothly increased in both groups; the increment of blood pressure was slightly greater in GLM002-SHR, but the increment of plasma ACE activity was proportionately similar in each group. In the aspects of the triglyceride, HDL and total cholesterol level, those levels were slightly different among each group. We also conducted clinical dosage of GLM002 to the patients who have mild and severe hypertension for approximately 7 weeks. Clinical treatments also showed remarkable efficiencies on blood pressure (systolic blood pressure, diastolic blood pressure), complete blood count (CBC) routine, differ count (NEUTRO, LYM, MONO, EOS and BASO) and R-chemistry. We conclude that GLM002, like already proven enalapril, plays a role as an angiotensin-converting enzyme inhibitor, and can be suggested as a drug candidate for curing hypertension.

Keywords

References

  1. Hypertension mechanism Irvine H;Page MD.
  2. Hypertension(Second Edition) Jacques G;Otto K;Pavel H;Marc C.
  3. Clin. Sci. v.60 no.4 Adrenergic facilitation by angiotensin: does it serve a physiological function? Zimmerman BG.
  4. Hypertension v.11 no.3 Local generation and release of angiotensin II in peripheral vascular tissue Mizuno K;Nakamura M;Higashimori K; Inagami T.
  5. Hypertension v.20 no.2 Tissue renin-angiotensin systems in renal hypertension Nishimura M;Milsted A;Block CH;Brosnihan KB;Ferrario CM.
  6. Biochem. pharmacol. v.27 no.5 Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase Erdos EF;Johnson A;Boyden NT.
  7. J. Hypertens. Suppl. v.12 no.2 Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study Lacoureiere Y;Lefebvre J;Nakhle G;Faison EP;Snavely DB;Nelson EB.
  8. Vasc. Med. v.1 no.2 The impact of angiotensin converting enzyme inhibitors on the arterial wall Lee AF;Struthers AD.
  9. Am. J. Cardiol. v.75 no.12 Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension Goldberg AI;Dunlay MC;Sweet CS.
  10. Br. J. Clin. Pharmacol. v.46 no.2 Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor Scholze J;Stapff M.
  11. Lancet. v.349 no.9054 Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Pitt B;Segal R;Martinez FA;Meurers G;Cowley AJ;Thomas I;Deedwania PC;Ney DE;Snavely DB;Chang PI.
  12. J. Vet. Med. Sci. v.54 no.1 Early development of spontaneous glomerular lesion in Syrian hamsters of APA strain Han JS;Norimatsu M;Itagaki S;Doi K.
  13. Lab Anim. v.24 no.1 Glomerular lipidosis in a Syrian hamster of the APA strain Norimatsu M;Doi M;Itagaki S;Honjo K;Mitsuoka T.
  14. Hypertension v.19 Increased vascular formation of angiotensin II in one-kidney, one clip hypertension Leite R;Salgado MC.
  15. Am. J. Cli. Pathol. v.66 no.2 A sensitive fluorimetric assay for serum angiotensin-converting enzyme Friedland J;Silverstein E.
  16. Hypertension An improved fluorometric assay of rat serum and plasma converting enzyme Santos RAS;Krieger EM;Greene LJ.
  17. Biol. Pharm. Bull. v.23 no.2 Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models Tokioka T;Shibasaki M;Fujimori A;Matsuda-Satoh Y;Uchida W;Inagaki O;Yanagisawa I.
  18. American Journal of Pathology v.88 no.3 Morphometric analysis of hypertension induced hypertrophy of rat thoracic aorta Wiener J;Loud AV;Giacomelli F;Anversa P.
  19. The Journal of Pharmacology and Experimental Therapeutics v.284 no.3 Antihypertensive and Natriuretic Effects of CGS 30440, a Dual Inhibitor of Angiotensin Converting Enzyme and Neutral Endopeptidese 24.11 Ricardo EC;Rajendra DG;Angelo JT;Lynne MO;Beatriz ND;Stephane De L;Rodney WL;Cynthia AF.
  20. The Journal of Pharmacology and Experimental Therapeutics v.291 no.1 Angiotensin II-Induced Renal Vasoconstriction in Genetic Hypertension Edwin KJ;William AH;Subharsh JV;CURTIS KK.